Thursday 16 October, 2025
Objectives: Different binding patterns of therapeutic antibodies impact the therapy effects. Novel bispecific antibodies (BsAb) may bind different targets on…
Read morePoster: Drug/Disease Modelling - Oncology
Circulating cell-free DNA size distribution as a prediction marker for early progression undergoing immune checkpoint inhibitors
Thursday 16 October, 2025
Introduction: Despite a significant proportion (20 to 40%)[1] of advanced cancer patients having long-term response to treatment with immune checkpoint inhibitors…
Read morePKPD model evaluating the ideal interplay between the PK and mechanism of activation of conditionally activated molecules
Thursday 16 October, 2025
Objectives: Conditionally activated molecules are designed to deliver a targeted therapy or reduce the off-tumor activity by exploiting specific properties…
Read morePopulation Pharmacokinetic/Pharmacodynamic Modelling of Cytokine Releasing Syndrome (CRS) Events during T cell Engager Therapy
Thursday 16 October, 2025
Objectives: T cell engager therapies can direct T cells to attack tumor cells, thereby creating an immunological synapse that results…
Read moreA generic modeling framework for dose regimen optimization and patient selection in radioligand therapy
Thursday 16 October, 2025
Introduction: The use of radioligand therapy (RLT) is gaining ground in oncology emerging as an essential pillar in cancer care,…
Read morePopulation PK and exposure-response modeling to support the design of trials with Debio 0123, a WEE1 inhibitor, in cancer patients
Thursday 16 October, 2025
Introduction: Debio 0123 (D0123) is an oral, brain-penetrant, highly selective WEE1 inhibitor that has demonstrated significant cell growth inhibition in…
Read morePharmacokinetic–pharmacodynamic modeling and treatment simulation of maintenance therapy for childhood acute lymphoblastic leukemia
Thursday 16 October, 2025
Introduction: Acute lymphoblastic leukemia (ALL) is one of the most common pediatric malignancies [1] and is treated with initial high-dose…
Read moreDevelopment of a pharmacokinetic-pharmacodynamic model to describe blood hepcidin levels in patients with myelofibrosis and assess target engagement of zilurgisertib, an ALK2 inhibitor
Thursday 16 October, 2025
Introduction: Anaemia is a predominant feature of myelofibrosis (MF), a type of myeloproliferative neoplasm, and is associated with poor prognosis…
Read moreA comparative benchmark study of empirical tumor size models in NSCLC clinical data
Thursday 16 October, 2025
Introduction: Tumor size dynamics models are the key data analytics tools for analysis of the surrogate biomarker data in oncology…
Read moreIntegration of clinical data and mechanistic model simulations highlights key parameters for design and selection of successful ADCs
Thursday 16 October, 2025
Introduction/Objectives: Antibody-Drug Conjugates (ADCs) aim at exploiting the targeted nature of monoclonal antibodies (mAb) to selectively deliver cytotoxic payloads into…
Read more